Genome sequencing of tumors are helping pathologist and physicians identify useful therapies for patients with unresponsive cancers
Step by step, progress is happening in the use of genome sequencing to advance personalized and precision medicine, with clinical laboratories and pathologists in the forefront of these developments. Much of this effort is focused on cancer and the sequencing of tumors.
One recent example comes from New York City, where the genomes of tumors of patients with unresponsive cancers were sequenced at the Institute for Precision Medicine at Weill Cornell and New York-Presbyterian Hospital Weill Cornell Medical Center. The outcomes of this effort demonstrates how the results of such testing can help patients who had not found an effective therapy to control their cancers.
The resulting study provides early evidence as to how precision medicine could transform cancer care. The team recruited 97 patients who had “exhausted every treatment available” according to Himisha Beltran, MD, the study’s lead author. The researchers performed whole exome sequencing on 154 tumors, and found an average of 16 mutations per patient.
Although the vast majority of those mutations require further study in order for scientists to understand their clinical significance, 114 of those mutations could either be treated immediately with available drugs or were treatable with therapies under development. The results were reviewed by a multidisciplinary board, which took into account the results of genome sequencing for each patient, as well as their medical histories and radiology reports. The board then generated individual treatment plans.
One patient experienced especially positive results: the “dramatic and durable remission” of an advanced bladder cancer. Such results are exciting for clinicians because they offer a glimpse of what is possible when treatment is so highly individualized.
Despite precision medicine’s promising future, there are issues for clinicians, researchers, and patients to overcome. Some of the therapies recommended by the reports and multidisciplinary boards are not yet available. For example, of the 97 patients in the Weill Cornell study, only 5 percent could follow the board’s recommendations, mostly because the therapies were either still in clinical trials or simply were not available.
Another issue is the learning curve for caregivers, clinicians, and others involved in the process. Such challenges, however, are typical for a field that is, by all accounts, still in its infancy. What is important for the pathology profession is how quickly clinical studies are published in peer-reviewed journals. It will take this evidence to encourage the Medicare program and private payers to make more informed coverage and reimbursement decisions.
On the other hand, it is tough to argue with the success stories associated with the use of gene sequencing in support of cancer care. Examples, such as the full recovery of the patient with bladder cancer in the Weill Cornell study, and that of Mark Gettis, the patient who experienced great results due to the tests done at CPD, are motivating both researchers and physicians to expand their knowledge of how to use these diagnostic tools.
This is an excerpt of a story that appeared on the pathology news site Dark Daily. Read the full article here.